Giving Chase in AD

While the Alzheimer's disease space is littered with failed disease-modifying compounds, Chase Pharmaceuticals Corp. is taking a different tack. The company is combining undisclosed molecules with marketed AD drugs to improve the side effect profiles of the marketed products. Chase expects last week's tranched $21 million series B round will give it four years of runway and get lead program CPC-201 through Phase II testing.

New investor New Rhein Healthcare Investors led the round. Also new to the syndicate were Edmond de Rothschild Investment Partners (EdRIP) and Cipla Ventures, which is the new VC arm of Indian pharma Cipla Ltd. Existing investor Brain Trust Accelerator Fund also participated...